17 results on '"Yilmaz Ciftdogan D"'
Search Results
2. Multisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study)
- Author
-
Dilek Yilmaz Ciftdogan, Yildiz Ekemen Keles, Adem Karbuz, Benhur Sirvan Cetin, Sefika Elmas Bozdemir, Eda Kepenekli Kadayifci, Ozge Metin Akcan, Arife Ozer, Tugba Erat, Murat Sutcu, Ayse Buyukcam, Nursen Belet, Emine Hafize Erdeniz, Nazan Dalgic Karabulut, Selda Hancerli Torun, Selim Oncel, Zerrin Orbak, Ozden Turel, Zeynep Gokce Gayretli Aydin, Omer Kilic, Aysun Yahsi, Ahu Kara Aksay, Zeynep Ergenc, Mey Talip Petmezci, Mehmet Burhan Oflaz, Remzi Sarikaya, Gülcin Otar Yener, Seval Ozen, Doruk Gul, Gazi Arslan, Soner Sertan Kara, Demet Demirkol, Pinar Yazici Ozkaya, Yilmaz Yozgat, Celal Varan, Manolya Kara, Gul Arga, Nurhayat Yakut, Ahmet Osman Kilic, Ozlem Cakici, Mehmet Kucuk, Ozge Kaba, Hatice Karaoglu Asrak, Burcu Bursal Duramaz, Tahir Dalkiran, Ayse Berna Anil, Mehmet Turgut, Bulent Karapinar, Ayper Somer, Ferhan Elmali, Ener Cagri Dinleyici, Ergin Ciftci, Ates Kara, İstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Murat Sütçü / 0000-0002-2078-9796, Doruk Gül / 0000-0003-2558-3719, Sütçü, Murat, Gül, Doruk, Murat Sütçü / ABG-7336-2021, Doruk Gül / AGJ-2448-2022, Murat Sütçü / 55499199300, Doruk Gül / 57222108765, Yilmaz Ciftdogan D., Ekemen Keles Y., Karbuz A., ÇETİN B. Ş., Elmas Bozdemir S., KEPENEKLİ KADAYİFCİ E., Metin Akcan O., Ozer A., Erat T., Sutcu M., et al., TÜREL, Özden, and {{contributorinst}}
- Subjects
Male ,Sars ,Turkey ,MIS-C ,shock ,Mucocutaneous Lymph Node Syndrome ,Sağlık Bilimleri ,Pediatrics ,Clinical Medicine (MED) ,DISEASE ,Çocuk Sağlığı ve Hastalıkları ,Child Health and Diseases ,Health Sciences ,Diagnosis ,Humans ,Klinik Tıp (MED) ,Glucocorticoids ,Kawasaki-Disease ,Fatigue ,Retrospective Studies ,child ,Internal Medicine Sciences ,Klinik Tıp ,Kawasaki disease ,SARS-CoV-2 ,Immunoglobulins, Intravenous ,COVID-19 ,Dahili Tıp Bilimleri ,CLINICAL MEDICINE ,Systemic Inflammatory Response Syndrome ,Tıp ,Pediatrics, Perinatology and Child Health ,Medicine ,Female ,PEDİATRİ ,Receptor - Abstract
© 2022 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).Aim: Multisystem inflammatory syndrome in children (MIS-C) may cause shock and even death in children. The aim of this study is to describe the clinical features, laboratory characteristics and outcome of children diagnosed with MIS-C in 25 different hospitals in Turkey. Methods: The retrospective study was conducted between 8 April and 28 October 2020 in 25 different hospitals from 17 cities. Data were collected from patients' medical records using a standardised form. Clinical and laboratory characteristics and outcomes according to different age groups, gender and body mass index percentiles were compared using multivariate logistic regression analysis. Results: The study comprised 101 patients, median age 7 years (interquartile range (IQR) 4.6–9.3); 51 (50.5%) were boys. Reverse-transcriptase polymerase chain reaction (PCR) assay was positive in 21/100 (21%) patients; 62/83 (74.6%) patients had positive serology for SARS-CoV-2. The predominant complaints were fever (100%), fatigue (n = 90, 89.1%), and gastrointestinal symptoms (n = 81, 80.2%). Serum C-reactive protein (in 101 patients, median 165 mg/L; range 112–228), erythrocyte sedimentation rate (73/84, median 53 mm/s; IQR 30–84) and procalcitonin levels (86/89, median 5 μg/L; IQR 0.58–20.2) were elevated. Thirty-eight patients (37.6%) required admission to intensive care. Kawasaki disease (KD) was diagnosed in 70 (69.3%) patients, 40 of whom had classical KD. Most patients were treated with intravenous immunoglobulin (n = 92, 91%) and glucocorticoids (n = 59, 58.4%). Seven patients (6.9%) died. Conclusion: The clinical spectrum of MIS-C is broad, but clinicians should consider MIS-C in the differential diagnosis when persistent fever, fatigue and gastrointestinal symptoms are prominent. Most patients diagnosed with MIS-C were previously healthy. Immunomodulatory treatment and supportive intensive care are important in the management of cases with MIS-C. Glucocorticoids and intravenous immunoglobulins are the most common immunomodulatory treatment options for MIS-C. Prompt diagnosis and prompt treatment are essential for optimal management.
- Published
- 2022
3. Serum Amyloid A Levels and Severity of COVID-19 in Children.
- Author
-
Tasar S, Karadag-Oncel E, Elvan-Tuz A, Sahin A, Ustundag G, Ekemen-Keles Y, Onur S, Isbilen-Basok B, Kara-Aksay A, and Yilmaz-Ciftdogan D
- Subjects
- Humans, Child, Serum Amyloid A Protein, Biomarkers, C-Reactive Protein, Severity of Illness Index, COVID-19
- Abstract
Objective: The aim of this study was to determine the availability of serum amyloid A (SAA) in the diagnosis of coronavirus disease 2019 (COVID-19), to asses disease severity and to predict hospitalization status., Methods: Between March, 2020 and March, 2021, a total of 80 children (40 cases with COVID-19 and 40 cases in healthy group) were included in this study. Patients were divided into two groups (mild and moderate/severe) to evaluate SAA levels in terms of clinical severity and also hospitalization status., Results: Comparisons between the two groups revealed that median SAA values were significantly higher in children with COVID-19 than in their healthy peers (21.45vs3.05 mg/L, P=0.002). There was no significant difference in the median serum SAA levels between mild and moderate/severe clinical disease (P=0.837). The SAA difference between the two groups with regards to hospitalization was not statistically significant (P=0.098)., Conclusions: Although SAA level was found to be higher in children with COVID 19 compared to healthy controls, the sensitivity of SAA for the disease was found to be low. In addition, there was no difference between the groups in terms of clinical severity.
- Published
- 2023
4. Differentiating abdominal pain due to COVID-19 associated multisystem inflammatory syndrome from children with acute appendicitis: a score system.
- Author
-
Toker Kurtmen B, Ekemen Keles Y, Tekindal MA, Koyluoglu G, and Yilmaz Ciftdogan D
- Subjects
- Humans, Child, Abdominal Pain etiology, Acute Disease, Systemic Inflammatory Response Syndrome complications, Coronavirus, COVID-19, Appendicitis diagnosis, Coronavirus Infections
- Abstract
Purpose: Differentiating abdominal pain due to coronavirus disease (COVID-19)-associated multisystem inflammatory syndrome (MIS-C) in children with acute appendicitis (AA) can cause diagnostic dilemmas. This study aimed to evaluate the efficacy of a previously described scoring system and improve its diagnostic ability in differentiating between these diseases., Methods: This study was conducted between March 2020 and January 2022. Patients who had MIS-C with gastrointestinal system (GIS) involvement and patients who underwent surgery for appendicitis were included. First, all patients were evaluated using the new scoring system (NSS). The groups were compared by adding new MISC-specific parameters to NSS. The scoring system was evaluated using propensity score matching (PSM)., Results: A total of 35 patients with abdominal pain due to GIS involvement in MIS-C (group A) and 37 patients with AA who had ALT, PRC, and D-dimer results at their first admission (group B) were included in the study. The mean age of patients in group A was lower than that of patients in group B (p < 0.001). False NSS positivity was found in 45.7% of the patients with MIS-C. Lymphocyte (p = 0.021) and platelet counts (p = 0.036) were significantly lower in the blood count and serum D-dimer (p = 0.034), C-reactive protein (CRP) (p < 0.001), and procalcitonin (p < 0.001) were significantly higher in the MIS-C group. We created a scoring system called the Appendicitis-MISC Score (AMS) using the NSS and new parameters. The sensitivity and specificity of AMS diagnostic scores were 91.9% and 80%, respectively., Conclusion: MIS-C with GIS involvement may present as acute abdomen. It is difficult to differentiate this condition from acute appendicitis. AMS has been shown to be useful for this differentiation., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
5. Influenza is more severe than our newest enemy (COVID-19) in hospitalized children: Experience from a tertiary center.
- Author
-
Tasar S, Karadag-Oncel E, Yilmaz-Ciftdogan D, Kara-Aksay A, Ekemen-Keles Y, Elvan-Tuz A, Ustundag G, Sahin A, Kanık MA, and Yilmaz N
- Subjects
- Child, Child, Hospitalized, Humans, Retrospective Studies, SARS-CoV-2, COVID-19 epidemiology, Coinfection, Influenza, Human complications, Influenza, Human epidemiology
- Abstract
Understanding differences in terms of clinical phenotypes and outcomes of coronavirus disease 2019 (COVID-19) compared with influenza is vital to optimizing the management of patients and planning healthcare. Herein, we aimed to investigate the clinical differences and outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza. We performed a retrospective study of hospitalized children who were positive for SARS-CoV-2 between March 2020 and March 2021 and for influenza between January 2016 and February 2020 in respiratory samples. The primary outcome of this study was pediatric intensive care unit (PICU) admission, and the secondary outcome was the need for respiratory support. A total of 74 patients with influenza and 71 who were positive for SARS-CoV-2 were included. The distribution among the sexes was similar, but patients with COVID-19 were older than patients with influenza (96 vs. 12, p < 0.001). In terms of underlying chronic diseases, the frequency was 26.7% in the COVID-19 group and 54% in the influenza group (p = 0.001). The comparison of symptoms revealed that fatigue, headache, nausea, vomiting, and abdominal pain occurred more frequently with COVID-19 (for all p < 0.05) and runny nose with influenza (p = 0.002). The frequency of admission to the PICU was relatively higher (18.9%) in the influenza group than with COVID-19 (2.8%) with a significant ratio (p = 0.001), secondary bacterial infections were observed more frequently in the influenza group (20.2% vs. 4.2%, p = 0.003). Some 88.7% of patients with COVID-19 did not need respiratory support, whereas 59.4% of patients with influenza did require respiratory support (p < 0.001). This study noted that influenza caused more frequent admissions to the PICU and a greater need for respiratory support in hospitalized pediatric patients than COVID-19., (© 2022 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
6. Correction to: Intestinal microbiota composition of children with infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome (MIS-C).
- Author
-
Suskun C, Kilic O, Yilmaz Ciftdogan D, Guven S, Karbuz A, Parlakay AO, Kara Y, Kacmaz E, Sahin A, Boga A, Kizmaz Isancli D, Gulhan B, Kanik-Yuksek S, Kiral E, Bozan G, Arslanoglu MO, Can Kizil M, Dinleyici M, Us T, Varis A, Kaya M, Vandenplas Y, and Cagri Dinleyici E
- Published
- 2022
- Full Text
- View/download PDF
7. Intestinal microbiota composition of children with infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and multisystem inflammatory syndrome (MIS-C).
- Author
-
Suskun C, Kilic O, Yilmaz Ciftdogan D, Guven S, Karbuz A, Ozkaya Parlakay A, Kara Y, Kacmaz E, Sahin A, Boga A, Kizmaz Isancli D, Gulhan B, Kanik-Yuksek S, Kiral E, Bozan G, Arslanoglu MO, Kizil MC, Dinleyici M, Us T, Varis A, Kaya M, Vandenplas Y, and Dinleyici EC
- Subjects
- Actinobacteria, Adult, Bacillus, Child, Feces microbiology, Firmicutes, Humans, Prospective Studies, SARS-CoV-2, Systemic Inflammatory Response Syndrome, COVID-19 complications, Gastrointestinal Microbiome genetics, Pediatric Obesity
- Abstract
Microbiota composition may play a role in the development, prognosis, or post-infection of COVID-19. There are studies evaluating the microbiota composition at the time of diagnosis and during the course of COVID-19, especially in adults, while studies in children are limited and no study available in children with multisystem inflammatory syndrome in children (MIS-C). This study was planned to compare intestinal microbiota composition in children diagnosed with MIS-C and acute COVID-19 infection with healthy children. In this prospective multicenter study, 25 children diagnosed with MIS-C, 20 with COVID-19 infection, and 19 healthy children were included. Intestinal microbiota composition was evaluated by 16 s rRNA gene sequencing. We observed changes of diversity, richness, and composition of intestinal microbiota in MIS-C cases compared to COVID-19 cases and in the healthy controls. The Shannon index was higher in the MIS-C group than the healthy controls (p < 0.01). At phylum level, in the MIS-C group, a significantly higher relative abundance of Bacteroidetes and lower abundance of Firmicutes was found compared to the control group. Intestinal microbiota composition changed in MIS-C cases compared to COVID-19 and healthy controls, and Faecalibacterium prausnitzii decreased; Bacteroides uniformis, Bacteroides plebeius, Clostridium ramosum, Eubacterium dolichum, Eggerthella lenta, Bacillus thermoamylovorans, Prevotella tannerae, and Bacteroides coprophilus were dominant in children with MIS-C. At species level, we observed decreased Faecalibacterium prausnitzii, and increased Eubacterium dolichum, Eggerthella lenta, and Bacillus thermoamylovorans in children with MIS-C and increased Bifidobacterium adolescentis and Dorea formicigenerasus in the COVID-19 group. Our study is the first to evaluate the microbiota composition in MIS-C cases. There is a substantial change in the composition of the gut microbiota: (1) reduction of F. prausnitzii in children with MIS-C and COVID-19; (2) an increase of Eggerthella lenta which is related with autoimmunity; and (3) the predominance of E. dolichum is associated with metabolic dysfunctions and obesity in children with MIS-C., Conclusions: Alterations of the intestinal microbiota might be part of pathogenesis of predisposing factor for MIS-C. It would be beneficial to conduct more extensive studies on the cause-effect relationship of these changes in microbiota composition and their effects on long-term prognosis., What Is Known: • Microbiota composition may play a role in the development, prognosis, or post-infection of COVID-19. • However, the number of studies on children is limited, and no study on multisystem inflammatory syndrome in children is currently available (MIS-C)., What Is New: • In individuals with MIS-C, the composition of the gut microbiota changed dramatically. • Decreased Faecalibacterium prausnitzii have been observed, increased Eggerthella lenta, which was previously linked to autoimmunity, and predominance of Eubacterium dolichum which was linked to metabolic dysfunction and obesity., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
8. Multisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study).
- Author
-
Yilmaz Ciftdogan D, Ekemen Keles Y, Karbuz A, Cetin BS, Elmas Bozdemir S, Kepenekli Kadayifci E, Metin Akcan O, Ozer A, Erat T, Sutcu M, Buyukcam A, Belet N, Erdeniz EH, Dalgic Karabulut N, Hancerli Torun S, Oncel S, Orbak Z, Turel O, Gayretli Aydin ZG, Kilic O, Yahsi A, Kara Aksay A, Ergenc Z, Petmezci MT, Oflaz MB, Sarikaya R, Otar Yener G, Ozen S, Gul D, Arslan G, Kara SS, Demirkol D, Yazici Ozkaya P, Yozgat Y, Varan C, Kara M, Arga G, Yakut N, Kilic AO, Cakici O, Kucuk M, Kaba O, Karaoglu Asrak H, Bursal Duramaz B, Dalkiran T, Berna Anil A, Turgut M, Karapinar B, Somer A, Elmali F, Dinleyici EC, Ciftci E, and Kara A
- Subjects
- Child, Fatigue, Female, Glucocorticoids therapeutic use, Humans, Immunoglobulins, Intravenous therapeutic use, Male, Retrospective Studies, SARS-CoV-2, Systemic Inflammatory Response Syndrome, Turkey epidemiology, COVID-19 complications, Mucocutaneous Lymph Node Syndrome
- Abstract
Aim: Multisystem inflammatory syndrome in children (MIS-C) may cause shock and even death in children. The aim of this study is to describe the clinical features, laboratory characteristics and outcome of children diagnosed with MIS-C in 25 different hospitals in Turkey., Methods: The retrospective study was conducted between 8 April and 28 October 2020 in 25 different hospitals from 17 cities. Data were collected from patients' medical records using a standardised form. Clinical and laboratory characteristics and outcomes according to different age groups, gender and body mass index percentiles were compared using multivariate logistic regression analysis., Results: The study comprised 101 patients, median age 7 years (interquartile range (IQR) 4.6-9.3); 51 (50.5%) were boys. Reverse-transcriptase polymerase chain reaction (PCR) assay was positive in 21/100 (21%) patients; 62/83 (74.6%) patients had positive serology for SARS-CoV-2. The predominant complaints were fever (100%), fatigue (n = 90, 89.1%), and gastrointestinal symptoms (n = 81, 80.2%). Serum C-reactive protein (in 101 patients, median 165 mg/L; range 112-228), erythrocyte sedimentation rate (73/84, median 53 mm/s; IQR 30-84) and procalcitonin levels (86/89, median 5 μg/L; IQR 0.58-20.2) were elevated. Thirty-eight patients (37.6%) required admission to intensive care. Kawasaki disease (KD) was diagnosed in 70 (69.3%) patients, 40 of whom had classical KD. Most patients were treated with intravenous immunoglobulin (n = 92, 91%) and glucocorticoids (n = 59, 58.4%). Seven patients (6.9%) died., Conclusion: The clinical spectrum of MIS-C is broad, but clinicians should consider MIS-C in the differential diagnosis when persistent fever, fatigue and gastrointestinal symptoms are prominent. Most patients diagnosed with MIS-C were previously healthy. Immunomodulatory treatment and supportive intensive care are important in the management of cases with MIS-C. Glucocorticoids and intravenous immunoglobulins are the most common immunomodulatory treatment options for MIS-C. Prompt diagnosis and prompt treatment are essential for optimal management., (© 2022 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).)
- Published
- 2022
- Full Text
- View/download PDF
9. COVID-19 associated multisystemic inflammatory syndrome in 614 children with and without overlap with Kawasaki disease-Turk MIS-C study group.
- Author
-
Yilmaz Ciftdogan D, Ekemen Keles Y, Cetin BS, Dalgic Karabulut N, Emiroglu M, Bagci Z, Buyukcam A, Erdeniz EH, Arga G, Yesil E, Cakici O, Karbuz A, Sahbudak Bal Z, Kara SS, Ozer A, Metin Akcan O, Elmas Bozdemir S, Anil AB, Uygun H, Kilic O, Hancerli Torun S, Umit Z, Sutcu M, Ozgokce Ozmen B, Karaoglu Asrak H, Alkan G, Kara Aksay A, Ugur C, Birbilen AZ, Bursal Duramaz B, Akyuz Ozkan E, Burakay O, Yildirim Arslan S, Karadag Oncel E, Celik SF, Kilic AO, Ozen S, Sarikaya R, Demirkol D, Arslan G, Turel O, Sert A, Sari E, Orbak Z, Sahin IO, Varan C, Akturk H, Tuter Oz SK, Durak F, Oflaz MB, Kara M, Karpuz D, Talip Petmezci M, Hatipoglu N, Oncel S, Turgut M, Elmali F, Somer A, Kuyucu N, Dinleyici EC, Kurugöl Z, Ciftci E, and Kara A
- Subjects
- Child, Child, Preschool, Humans, Lethargy, Procalcitonin, Retrospective Studies, SARS-CoV-2, Systemic Inflammatory Response Syndrome, COVID-19 complications, COVID-19 diagnosis, Mucocutaneous Lymph Node Syndrome complications, Mucocutaneous Lymph Node Syndrome diagnosis, Mucocutaneous Lymph Node Syndrome drug therapy
- Abstract
Multisystemic inflammatory syndrome (MIS-C) diagnosis remains difficult because the clinical features overlap with Kawasaki disease (KD). The study aims to highlight the clinical and laboratory features and outcomes of patients with MISC whose clinical manifestations overlap with or without KD. This study is a retrospective analysis of a case series designed for patients aged 1 month to 18 years in 28 hospitals between November 1, 2020, and June 9, 2021. Patient demographics, complaints, laboratory results, echocardiographic results, system involvement, and outcomes were recorded. A total of 614 patients were enrolled; the median age was 7.4 years (interquartile range (IQR) 3.9-12 years). A total of 277 (45.1%) patients with MIS-C had manifestations that overlapped with KD, including 92 (33.3%) patients with complete KD and 185 (66.7%) with incomplete KD. Lymphocyte and platelet counts were significantly lower in patients with MISC, overlapped with KD (lymphocyte count 1080 vs. 1280 cells × μL, p = 0.028; platelet count 166 vs. 216 cells × 10
3 /μL, p < 0.001). The median serum procalcitonin levels were statistically higher in patients overlapped with KD (3.18 vs. 1.68 µg/L, p = 0.001). Coronary artery dilatation was statistically significant in patients with overlap with KD (13.4% vs. 6.8%, p = 0.007), while myocarditis was significantly more common in patients without overlap with KD features (2.6% vs 7.4%, p = 0.009). The association between clinical and laboratory findings and overlap with KD was investigated. Age > 12 years reduced the risk of overlap with KD by 66% (p < 0.001, 95% CI 0.217-0.550), lethargy increased the risk of overlap with KD by 2.6-fold (p = 0.011, 95% CI 1.244-5.439), and each unit more albumin (g/dl) reduced the risk of overlap with KD by 60% (p < 0.001, 95% CI 0.298-0.559)., Conclusion: Almost half of the patients with MISC had clinical features that overlapped with KD; in particular, incomplete KD was present. The median age was lower in patients with KD-like features. Lymphocyte and platelet counts were lower, and ferritin and procalcitonin levels were significantly higher in patients with overlap with KD., What Is Known: • In some cases of MIS-C, the clinical symptoms overlap with Kawasaki disease. • Compared to Kawasaki disease, lymphopenia was an independent predictor of MIS-C., What Is New: • Half of the patients had clinical features that overlapped with Kawasaki disease. • In patients whose clinical features overlapped with KD, procalcitonin levels were almost 15 times higher than normal. • Lethargy increased the risk of overlap with KD by 2.6-fold in MIS-C patients. • Transient bradycardia was noted in approximately 10% of our patients after initiation of treatment., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2022
- Full Text
- View/download PDF
10. Coronavirus disease 2019 in healthy children: What is the effect of household contact?
- Author
-
Ustundag G, Yilmaz-Ciftdogan D, Kara-Aksay A, Sahin A, Ekemen-Keles Y, Orsdemir-Hortu H, Kanik A, Yuksel NC, Arslan FD, and Yilmaz N
- Subjects
- Adult, Child, Family Characteristics, Female, Humans, SARS-CoV-2, COVID-19
- Abstract
Background: Coronavirus disease 2019 (COVID-19) in children is milder than in adults. Household virus exposure may affect clinical severity. We aimed to determine the household contact history of patients and its influence on the clinical stage., Methods: One hundred and seventy-three pediatric patients with COVID-19 as diagnosed with positive real-time polymerase chain reaction for severe acute respiratory syndrome coronavirus-2 aged 1 month to 18 years were included. Demographic data, laboratory and clinical findings, and the history of household contact of the patients were obtained. They were classified according to their clinical stage as mild or moderate-severe., Results: Sixty patients (34.7%) were asymptomatic, and 113 were symptomatic (65.3%). Of the 173 patients, 138 (79.8%) had at least one family member in the household who was diagnosed as having COVID-19. Hemoglobin, absolute neutrophil count, and absolute neutrophil count /absolute lymphocyte count ratio decreased significantly in patients with household contact. The presence of a household contact did not have a significant effect on the presence of symptoms, clinical course, age, and the sex of the patients. The need for hospitalization was less in the group that had household contact. Being 0-12 months, being female, and being a patient without household contact were independent factors associated with higher hospitalization ratios in logistic regression analysis., Conclusions: In this study, we found that household contact history did not significantly affect presenting symptoms and clinical course. We detected the rate of hospitalization to be less in the group with only household contact., (© 2021 Japan Pediatric Society.)
- Published
- 2022
- Full Text
- View/download PDF
11. A rare case series of central nervous system cystic echinococcosis.
- Author
-
Elvan-Tuz A, Karadag-Oncel E, Kara-Aksay A, Sarioglu FC, Karadag A, and Yilmaz-Ciftdogan D
- Subjects
- Adolescent, Central Nervous System, Child, Diagnosis, Differential, Female, Headache, Humans, Male, Echinococcosis diagnostic imaging, Echinococcosis surgery
- Abstract
Introduction: A total of three cases of childhood central nervous system (CNS) echinococcosis with spinal or posterior fossa involvement having rare localizations, have been presented., Case Presentation: A 7-year-old boy with spinal involvement applied to our hospital with left leg weakness and inability to walk. A 16-year-old girl with posterior fossa involvement had peripheral facial paralysis, while a 9-year-old girl had headache and vomiting. These cases, diagnosed with cystic echinococcosis with the necessary laboratory and imaging methods, improved with appropriate medical treatment and surgery., Discussion: Especially in endemic areas, it should be kept in mind that cystic echinococcosis may present with CNS involvement and should become to mind in the differential diagnosis when neurological findings are detected. Lay Summary: With this report, we attempted to share our experience with cystic echinococcosis in the spinal region and posterior fossa in three children over 1 year, including a description of associated signs and symptoms as well as laboratory and radiological findings. It should be kept in mind that cystic echinococcosis may present with CNS involvement in endemic areas and should be considered in the differential diagnosis when neurological findings are detected. Afterward, the diagnosis should be confirmed with appropriate laboratory and imaging methods. In these cases, rapid recovery can be achieved with appropriate surgical intervention as well as medical treatment., (© The Author(s) [2021]. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
12. Epidemiological, Clinical, and Laboratory Features of Children With COVID-19 in Turkey.
- Author
-
Karbuz A, Akkoc G, Bedir Demirdag T, Yilmaz Ciftdogan D, Ozer A, Cakir D, Hancerli Torun S, Kepenekli E, Erat T, Dalgic N, Ilbay S, Karaaslan A, Erdeniz EH, Aygun FD, Bozdemir SE, Hatipoglu N, Emiroglu M, Sahbudak Bal Z, Ciftci E, Bayhan GI, Gayretli Aydin ZG, Ocal Demir S, Kilic O, Hacimustafaoglu M, Sener Okur D, Sen S, Yahsi A, Akturk H, Cetin B, Sutcu M, Kara M, Uygun H, Tural Kara T, Korukluoglu G, Akgun O, Üstündağ G, Demir Mis M, Sali E, Kaba O, Yakut N, Kılıc O, Kanik MK, Cetin C, Dursun A, Cicek M, Kockuzu E, Sevketoglu E, Alkan G, Guner Ozenen G, İnce E, Baydar Z, Ozkaya AK, Ovali HF, Tekeli S, Celebi S, Cubukcu B, Bal A, Khalilova F, Kose M, Hatipoglu HU, Dalkiran T, Turgut M, Basak Altas A, Selcuk Duru HN, Aksay A, Saglam S, Sari Yanartas M, Ergenc Z, Akin Y, Duzenli Kar Y, Sahin S, Tuteroz SK, Bilen NM, Ozdemir H, Senoglu MC, Pariltan Kucukalioglu B, Besli GE, Kara Y, Turan C, Selbest Demirtas B, Celikyurt A, Cosgun Y, Elevli M, Sahin A, Bahtiyar Oguz S, Somer A, Karadag B, Demirhan R, Turk Dagi H, Kurugol Z, Taskin EC, Sahiner A, Yesil E, Ekemen Keles Y, Sarikaya R, Erdem Eralp E, Ozkinay F, Konca HK, Yilmaz S, Gokdemir Y, Arga G, Ozen S, Coksuer F, Vatansever G, Tezer H, and Kara A
- Abstract
Objectives: The aim of this study is to identify the epidemiological, clinical, and laboratory features of coronavirus disease 2019 (COVID-19) in children. Methods: A retrospective study was conducted by pediatric infectious disease specialists from 32 different hospitals from all over Turkey by case record forms. Pediatric cases who were diagnosed as COVID-19 between March 16, 2020, and June 15, 2020 were included. Case characteristics including age, sex, dates of disease onset and diagnosis, family, and contact information were recorded. Clinical data, including the duration and severity of symptoms, were also collected. Laboratory parameters like biochemical tests and complete blood count, chest X-ray, and chest computed tomography (CT) were determined. Results: There were 1,156 confirmed pediatric COVID-19 cases. In total, male cases constituted 50.3% ( n = 582) and females constituted 49.7% ( n = 574). The median age of the confirmed cases was 10.75 years (4.5-14.6). Of the total cases, 90 were younger than 1 year of age (7.8%), 108 were 1-3 years of age (9.3%), 148 were 3-6 years of age (12.8%), 298 were 6-12 years of age (25.8%), 233 were 12-15 years of age (20.2%), and 268 cases were older than 15 years of age (23.2%). The most common symptom of the patients at the first visit was fever (50.4%) ( n = 583) for a median of 2 days (IQR: 1-3 days). Fever was median at 38.4°C (38.0-38.7°C). The second most common symptom was cough ( n = 543, 46.9%). The other common symptoms were sore throat ( n = 143, 12.4%), myalgia ( n = 141, 12.2%), dyspnea ( n = 118, 10.2%), diarrhea ( n = 112, 9.7%), stomachache ( n = 71, 6.1%), and nasal discharge ( n = 63, 5.4%). When patients were classified according to disease severity, 263 (22.7%) patients were asymptomatic, 668 (57.7%) patients had mild disease, 209 (18.1%) had moderate disease, and 16 (1.5%) cases had severe disease. One hundred and forty-nine (12.9%) cases had underlying diseases among the total cases; 56% of the patients who had severe disease had an underlying condition ( p < 0.01). The need for hospitalization did not differ between patients who had an underlying condition and those who do not have ( p = 0.38), but the need for intensive care was higher in patients who had an underlying condition ( p < 0.01). Forty-seven (31.5%) of the cases having underlying conditions had asthma or lung disease (38 of them had asthma). Conclusions: To the best of our knowledge, this is one of the largest pediatric data about confirmed COVID-19 cases. Children from all ages appear to be susceptible to COVID-19, and there is a significant difference in symptomatology and laboratory findings by means of age distribution., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Karbuz, Akkoc, Bedir Demirdag, Yilmaz Ciftdogan, Ozer, Cakir, Hancerli Torun, Kepenekli, Erat, Dalgic, Ilbay, Karaaslan, Erdeniz, Aygun, Bozdemir, Hatipoglu, Emiroglu, Sahbudak Bal, Ciftci, Bayhan, Gayretli Aydin, Ocal Demir, Kilic, Hacimustafaoglu, Sener Okur, Sen, Yahsi, Akturk, Cetin, Sutcu, Kara, Uygun, Tural Kara, Korukluoglu, Akgun, Üstündağ, Demir Mis, Sali, Kaba, Yakut, Kılıc, Kanik, Cetin, Dursun, Cicek, Kockuzu, Sevketoglu, Alkan, Guner Ozenen, İnce, Baydar, Ozkaya, Ovali, Tekeli, Celebi, Cubukcu, Bal, Khalilova, Kose, Hatipoglu, Dalkiran, Turgut, Basak Altas, Selcuk Duru, Aksay, Saglam, Sari Yanartas, Ergenc, Akin, Duzenli Kar, Sahin, Tuteroz, Bilen, Ozdemir, Senoglu, Pariltan Kucukalioglu, Besli, Kara, Turan, Selbest Demirtas, Celikyurt, Cosgun, Elevli, Sahin, Bahtiyar Oguz, Somer, Karadag, Demirhan, Turk Dagi, Kurugol, Taskin, Sahiner, Yesil, Ekemen Keles, Sarikaya, Erdem Eralp, Ozkinay, Konca, Yilmaz, Gokdemir, Arga, Ozen, Coksuer, Vatansever, Tezer and Kara.)
- Published
- 2021
- Full Text
- View/download PDF
13. One year period of invasive pneumococcal disease in children from a tertiary care hospital in Turkey in the post-vaccine era.
- Author
-
Ustundag G, Karadag-Oncel E, Sen-Tas S, Kara-Aksay A, Yilmaz-Ciftdogan D, Yilmaz N, and Ceyhan M
- Subjects
- Child, Drug Resistance, Bacterial, Humans, Infant, Macrolides, Pneumococcal Vaccines, Serogroup, Serotyping, Tertiary Care Centers, Turkey, Anti-Bacterial Agents therapeutic use, Pneumococcal Infections
- Abstract
The incidence of invasive pneumococcal disease (IPD) has decreased after pneumococcal conjugate vaccine used; however, a breakthrough infection may still be seen after vaccination. In this study, eight pediatric inpatients and nine episodes with IPD in our center were included. Their age and gender, diagnoses, facilitating factors, the status of immunization and the antibiotic resistance of Pneumococci, serotypes of Pneumococci were noted. The isolates were subjected to disc susceptibility tests for penicillin, macrolides, and fluoroquinolones, according to the guidelines of the Clinical and Laboratory Standards Institute. Of the vaccinated seven cases, four of them (57.1%) developed IPD which their serogroups were in vaccine content. It was observed that all four cases in question had an underlying facilitating factor. Pneumococcal antibiotic susceptibility is also crucial. Three of nine isolates (33.4%) were resistant, and one isolate (11.2%) was intermediate susceptible to penicillin. Six of the nine isolates (66.7%) had macrolide resistance in our investigation. Invasive pneumococcal infections with serogroups that exist in pneumococcal conjugate vaccine content may occur in vaccinated individuals.
- Published
- 2021
- Full Text
- View/download PDF
14. Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children aged less than five years.
- Author
-
Ceyhan M, Karadag-Oncel E, Hascelik G, Ustundag G, Gurbuz V, Samlioglu P, Yilmaz N, Ozsurekci Y, Yilmaz E, Aykac K, Oz FN, Uzum O, Orsdemir-Hortu H, Tanir G, Yilmaz-Ciftdogan D, and Kurugol Z
- Subjects
- Carrier State epidemiology, Child, Child, Preschool, Cross-Sectional Studies, Humans, Infant, Nasopharynx, Pneumococcal Vaccines, Serogroup, Turkey epidemiology, Pneumococcal Infections epidemiology, Pneumococcal Infections prevention & control, Streptococcus pneumoniae
- Abstract
Purpose: In Turkey, pneumococcal conjugate vaccine (PCV) was introduced to the national immunization program as PCV7 in 2008, and was replaced with PCV13 in 2011. The aim of the study was to demonstrate the pneumococcal carriage rate and the serotype distribution in healthy children under 5 years in Turkey who were vaccinated with PCV13., Methods: We conducted a cross-sectional study including the collection of questionnaire data and nasopharyngeal (NP) specimens among children aged <5 years from five centers from March 2019 to March 2020. Pneumococcal isolates were identified using optochin sensitivity and bile solubility. Serotyping was performed using a latex agglutination kit and Quellung reaction., Results: NP swab samples were collected from 580 healthy children. The observed overall carriage rate was 17.8%. None of the hypothesised predictors of S. pneumoniae carriage, except maternal education level was statistically significant (p = 0.017). High maternal education level appeared to decrease the risk (lower vs. higher maternal education OR: 1.992 [95% CI; 1.089-3.643], p = 0.025). The overall NP S. pneumoniae carriage prevalence for the PCV13-vaccinated children was 17.8% (103/580). The most common serotypes detected were serotype 15B (n = 10, 9.7%), serotype 23F (n = 9, 8.7%), serotype 23A (n = 9, 8.7%), serotype 11A (n = 7, 6.7%), serotype 19F (n = 5, 4.8%) and serotype 15F (n = 5, 4.8%). Of the isolates, 28 (27.2%) were in PCV13 vaccine strains (VSs), and 75 (72.8%) strains were non-VS. The serotype coverage rate was 27.2% for PCV13., Conclusion: The overall S. pneumoniae carriage rate was higher than in earlier studies from Turkey. Post-vaccine era studies from around the world have reported a decrease in VS serotypes and a 'serotype replacement' to non-VS serotypes, as we determined in our study., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
15. Prevalence of Protective Measles Virus Antibody Levels in Umbilical Cord Blood Samples and Sera of Mothers and Transplacental Transport Ratio in Turkey.
- Author
-
Cetin Coban S, Temel F, Duman P, Cosgun Y, Ozarslan F, Kayman T, Guven S, Bezirganoglu H, Gunes O, Yilmaz Ciftdogan D, Karadagli EE, Kaya C, and Kara A
- Subjects
- Adult, Antibodies, Viral blood, Female, Fetal Blood, Hospitals, Humans, Immunoglobulin G blood, Infant, Newborn immunology, Maternal-Fetal Exchange, Measles prevention & control, Mothers, Pregnancy, Prevalence, Regression Analysis, Surveys and Questionnaires, Turkey, Young Adult, Immunity, Maternally-Acquired immunology, Measles immunology, Measles Vaccine immunology, Measles virus immunology
- Abstract
In Turkey, the Measles Elimination Program has been implemented since 2002. The aim of this study was to evaluate the measles-specific antibody levels of mothers admitted to a hospital for birth and their infants, to determine the factors influencing the antibody levels of both, and to evaluate the transplacental transport ratio. We selected healthy women who came to the hospital for birth and their healthy newborns. We collected blood samples from 1,547 mothers and 1,529 infants. The protective prevalence of measles antibody levels of mothers was 80% (95% confidence interval [CI]: 78-82%) and that of newborns was 85% (95% CI: 83-86%). The antibody levels of mothers and newborns were positively linearly correlated (R: 0.922, p < 0.001) and were associated with parity (p < 0.001). The ratio of neonatal to maternal antibody levels increased with gestational age. The protective levels were 1.6 times higher (95% CI: 1.1-2.4) in mothers ≥ 32 years of age and 2.1 times higher (95% CI: 1.4-3.3) in naturally immune mothers. Two factors affecting the antibody levels of newborns were the mothers' antibody levels and their immunization status. The antibody level of mother was the most significant factor that influenced the infant's antibody level. Vaccination of women before pregnancy could enhance passive antibody protection by increasing the level of transplacental transmission.
- Published
- 2019
- Full Text
- View/download PDF
16. The evaluation of safety and efficacy of colistin use in pediatric intensive care unit: Results from two reference hospitals and review of literature.
- Author
-
Sahbudak Bal Z, Kamit Can F, Yazici P, Berna Anil A, Duyu M, Yilmaz Ciftdogan D, Nisel Yilmaz O, Cilli F, and Karapinar B
- Subjects
- Administration, Intravenous, Child, Preschool, Critical Illness, Gram-Negative Bacterial Infections mortality, Humans, Immunologic Deficiency Syndromes complications, Immunologic Deficiency Syndromes drug therapy, Immunologic Deficiency Syndromes mortality, Intensive Care Units, Pediatric, Kidney drug effects, Referral and Consultation, Retrospective Studies, Sepsis drug therapy, Sepsis etiology, Sepsis mortality, Treatment Outcome, Colistin administration & dosage, Colistin adverse effects, Drug Resistance, Multiple, Bacterial, Gram-Negative Bacterial Infections drug therapy
- Abstract
Colistin, an old cationic polypeptide antibiotic, have been reused due to rising incidence of infections caused by multi-drug resistant (MDR) Gram-negative microorganisms and the lack of new antibiotics. Therefore, we evaluated safety and efficacy of colistin in treatment of these infections. This study included 104 critically ill children with a median age of 55,9 months between January 2011 and January 2016. Nephrotoxicity occurred in 11 (10.5%) patients. Nephrotoxicity occurred between the third and seventh day of treatment in 63% of colistin induced nephrotoxicity episodes. The subgroup analysis between the patients who developed nephrotoxicity during colistin treatment and those that did not, showed no significant difference in terms of age, underlying disease, cause for PICU admission and type of infection required colistin treatment, P values were 0.615, 0.762, 0.621, 0.803, respectively. All patients were receiving a concomitant nephrotoxic agent (P = 0,355). The majority of the patients (52%) were having primary or secondary immune deficiency in treatment failure group and the most common cause of PICU admission was sepsis in treatment failure group, P values were 0.007 and 0.045, respectively. Mortality attributed to colistin failure and crude mortality were 14.4% and 29.8%, respectively. In conclusion, colistin may have a role in the treatment of infections caused by multidrug-resistant Gram-negative bacteria in critically ill children. However, the patients have to be followed for side effects throughout colistin treatment, not for only early stage. And the clinicians should be aware of increase in the rate of nephrotoxicity in patients those have been receiving a concomitant nephrotoxic agent., (Copyright © 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
17. Pure Red Cell Aplasia Due to Parvovirus B19: Erythropoietin-Resistant Anemia in a Pediatric Kidney Recipient.
- Author
-
Malbora B, Saritas S, Ataseven E, Belen B, Alparslan C, Yavascan O, Yilmaz Ciftdogan D, Atabay B, and Turker M
- Subjects
- Adolescent, Blood Transfusion, Drug Resistance, Erythema Infectiosum diagnosis, Erythema Infectiosum drug therapy, Erythema Infectiosum immunology, Erythropoietin therapeutic use, Hematinics therapeutic use, Humans, Immunocompromised Host, Immunoglobulins, Intravenous therapeutic use, Kidney Failure, Chronic diagnosis, Kidney Failure, Chronic etiology, Male, Nephritis, Hereditary complications, Opportunistic Infections diagnosis, Opportunistic Infections drug therapy, Opportunistic Infections immunology, Red-Cell Aplasia, Pure diagnosis, Red-Cell Aplasia, Pure drug therapy, Red-Cell Aplasia, Pure immunology, Treatment Outcome, Erythema Infectiosum virology, Immunosuppressive Agents adverse effects, Kidney Failure, Chronic surgery, Kidney Transplantation adverse effects, Opportunistic Infections virology, Red-Cell Aplasia, Pure virology
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.